229 related articles for article (PubMed ID: 24518783)
1. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.
Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC
J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783
[TBL] [Abstract][Full Text] [Related]
2. Expectant management of veterans with early-stage prostate cancer.
Filson CP; Shelton JB; Tan HJ; Kwan L; Skolarus TA; Saigal CS; Litwin MS
Cancer; 2016 Feb; 122(4):626-33. PubMed ID: 26540451
[TBL] [Abstract][Full Text] [Related]
3. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
4. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661
[TBL] [Abstract][Full Text] [Related]
5. Population-based assessment of determining predictors for quality of prostate cancer surveillance.
Chamie K; Williams SB; Hershman DL; Wright JD; Nguyen PL; Hu JC
Cancer; 2015 Dec; 121(23):4150-7. PubMed ID: 26307939
[TBL] [Abstract][Full Text] [Related]
6. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ
JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425
[TBL] [Abstract][Full Text] [Related]
7. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
[TBL] [Abstract][Full Text] [Related]
8. Racial Disparities in Active Surveillance for Prostate Cancer.
Krishna S; Fan Y; Jarosek S; Adejoro O; Chamie K; Konety B
J Urol; 2017 Feb; 197(2):342-349. PubMed ID: 27596691
[TBL] [Abstract][Full Text] [Related]
9. Variation in the use of active surveillance for low-risk prostate cancer.
Löppenberg B; Friedlander DF; Krasnova A; Tam A; Leow JJ; Nguyen PL; Barry H; Lipsitz SR; Menon M; Abdollah F; Sammon JD; Sun M; Choueiri TK; Kibel AS; Trinh QD
Cancer; 2018 Jan; 124(1):55-64. PubMed ID: 28902401
[TBL] [Abstract][Full Text] [Related]
10. Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.
Liu Y; Hall IJ; Filson C; Howard DH
Urol Oncol; 2021 Jul; 39(7):432.e1-432.e10. PubMed ID: 33308973
[TBL] [Abstract][Full Text] [Related]
11. Physician variation in management of low-risk prostate cancer: a population-based cohort study.
Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD
JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650
[TBL] [Abstract][Full Text] [Related]
12. Physician visits prior to treatment for clinically localized prostate cancer.
Jang TL; Bekelman JE; Liu Y; Bach PB; Basch EM; Elkin EB; Zelefsky MJ; Scardino PT; Begg CB; Schrag D
Arch Intern Med; 2010 Mar; 170(5):440-50. PubMed ID: 20212180
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns for older veterans with localized prostate cancer.
Hoffman RM; Shi Y; Freedland SJ; Keating NL; Walter LC
Cancer Epidemiol; 2015 Oct; 39(5):769-77. PubMed ID: 26228494
[TBL] [Abstract][Full Text] [Related]
14. More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.
Eifler JB; Alvarez J; Koyama T; Conwill RM; Ritch CR; Hoffman KE; Resnick MJ; Penson DF; Barocas DA;
J Urol; 2017 Mar; 197(3 Pt 1):614-620. PubMed ID: 27984110
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.
Macleod LC; Yabes JG; Fam MM; Bandari J; Yu M; Maganty A; Furlan A; Filson CP; Davies BJ; Jacobs BL
Eur Urol Focus; 2020 Mar; 6(2):242-248. PubMed ID: 31031042
[TBL] [Abstract][Full Text] [Related]
16. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
17. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
Loeb S; Walter D; Curnyn C; Gold HT; Lepor H; Makarov DV
J Urol; 2016 Sep; 196(3):721-6. PubMed ID: 26946161
[TBL] [Abstract][Full Text] [Related]
18. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
Herden J; Weissbach L
World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
[TBL] [Abstract][Full Text] [Related]
19. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Beebe-Dimmer JL; Ruterbusch JJ; Cooney KA; Bolton A; Schwartz K; Schwartz AG; Heath E
Cancer Med; 2019 Jun; 8(6):3325-3335. PubMed ID: 31094098
[TBL] [Abstract][Full Text] [Related]
20. [Patterns of care of patients with localized prostate cancer in Germany: a health care study with focus on active surveillance].
Chun FK; Becker A; Kluth LA; Seiler D; Schnell D; Fisch M; Graefen M; Weissbach L
Urologe A; 2015 Jan; 54(1):6-13. PubMed ID: 25391440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]